Organogenesis Holdings (ORGO) Capital Expenditures Growth (1y) (2019 - 2026)
Organogenesis Holdings (ORGO) Capital Expenditures Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 90.13 Bn | 88.27 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.98 Bn | 32.24 Bn | 1.97 Bn | 32.28% |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | -38.20% |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | -15.72% |
| 5 | United Therapeutics | 23.08 Bn | 20.93 Bn | 648.10 Mn | 32.98% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.38 Bn | 18.57 Bn | 1.16 Bn | -6.34% |
| 8 | Neurocrine Biosciences | 17.80 Bn | 16.48 Bn | 800.70 Mn | -86.92% |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | -21.54% |
| 10 | Organogenesis Holdings | 330.36 Mn | 238.26 Mn | 11.46 Mn | -13.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.24% |
| Dec 31, 2025 | 38.41% |
| Sep 30, 2025 | -13.00% |
| Jun 30, 2025 | 9.71% |
| Mar 31, 2025 | 361.32% |
| Dec 31, 2024 | 1.11% |
| Sep 30, 2024 | -86.59% |
| Jun 30, 2024 | 3,288.46% |
| Mar 31, 2024 | -60.42% |
| Dec 31, 2023 | -68.81% |
| Sep 30, 2023 | 84.18% |
| Jun 30, 2023 | -100.95% |
| Mar 31, 2023 | 6.26% |
| Dec 31, 2022 | 103.86% |
| Sep 30, 2022 | -37.72% |
| Jun 30, 2022 | 153.20% |
| Mar 31, 2022 | -62.30% |
| Dec 31, 2021 | -3.53% |
| Sep 30, 2021 | 185.57% |
| Jun 30, 2021 | 99.86% |